Amine to Alkene Conversion on Intact Proteins

Technology #ua17-087

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Diana Knyazeva
graduate student, 26 Chemistry & Biochemistry
Stephanie Jensen
graduate student (graduated), 26 Chemistry & Biochemistry
John Jewett
Assistant Professor, Chemistry & Biochemistry
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Title: Amine to Alkene Conversion on Intact Proteins

 

Invention: This technology provides the ability to selectively convert lysine into a terminal alkene with aryl diazonium ions. Proteins can be selectively modified to make stapled cyclic peptides or other drug-like molecules.

 

Background: In 2015, the global protein therapeutics market grew to nearly $174.7 billion due to trends in targeted therapies that resulted in fewer side effects. Monoclonal antibodies and biologics are the largest portion of newer medications in development, leaving room for the development of novel pathways and techniques to fuel the creation of new therapies.

 

Applications:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostic assay companies
  • Research centers
  • Academic laboratories

 

Advantages:

  • Provides a novel technique for pharmaceutical companies
  • Quick production/disposal

 

Licensing Manager:

Paul Eynott

PaulE@tla.arizona.edu

(520) 471-2687